
KEMH ROTEM Algorithm for Critical Bleeding

Key Points: This algorithm should be used in conjunction with the KEMH Blood Product Guidelines for Major Obstetric Haemorrhage. Only treat abnormal values if active bleeding or at high risk of bleeding. Consider early tranexamic acid (1g IV) in all critical bleeding situations. Repeat ROTEM analysis 10 mins after intervention to assess response.



Fibrinogen Dosing Guide

FIBTEM A5 Target: ≥12mm FIBTEM A5 Cryoprecipitate Fibrinogen Concentrate 7-10mm 1-2 doses 2g ≤6mm 2 doses 4g

Oryoprecipitate is the default product for fibrinogen replacement in the majority of bleeding cases at KEMH. It is generally available within 10 minutes of the request being made. One dose is equivalent to 10 whole blood units or 5 apheresis units and may be supplied as a combination of these units.

Fibrinogen Concentrate

Guidelines For Use

- Should only be considered in exceptional circumstances and with consultant anaesthetist or haematologist approval.
- Fibrinogen concentrate may be indicated instead of, or in addition to, oryoprecipitate if the FIBTEM A5 is somm in patients experiencing life threatening bleeding, or if there is critical bleeding with a high suspicion of occurrently.
- Use at higher FIBTEM values may be appropriate in patients refusing oryoprecipitate.

<u>Administration</u>

 Reconstitute 1g in 50ml warm sterile water (use prepared kit in fluid warmer).
 Swirl gently and do not shake (to avoid foaming). Administer each 1g via syringe driver over 2-4 mins if life-threatening haemorrhage or over 10 mins if not.

Prothrombinex


- 1. Haematologist approval required
- Consider as an alternative to FFP for patients with coagulation factor deficiency (e.g. prolonged EXTEM CT see above) in the following circumstances:
- Circulatory overload
 - Rapid correction in extreme coagulopathy

Key Contact Information

- 1 Bloodbank: dial 82748
- 2. Duty Anaesthetist: *41225 (internal) or 0420 302 571
- Theatre co-ordinator: *41220 (internal) or 0424 148 574
- On call haematologist: via switchboard on 08 6458 2222
- Theatres 1-4: 82211, 82212, 82213 and 82214 respectively. Theatre 5: dial 81462
- ASCU dial 82155/6, Delivery suite co-ordinator: pager 3313

SCGH ROTEM Algorithm for Critical Bleeding

Key Points: This algorithm should be used in conjunction with the SCGH Critical Bleeding Protocol. Only treat abnormal values if active bleeding or at high risk of bleeding. Repeat ROTEM analysis 10 mins after intervention to assess response.




Fibrinogen Dosing Guide FIBTEM A5 Target: ≥12mm FIBTEM A5 Increase required Cryoprecipitate* 9-10mm 2-3 mm 10 Units 4-5 mm 15 Units 7-8mm 4-6mm 6-8 mm 20 Units <4mm ≥9mm 20-25 Units *Cryoprecipitate dosing is for standard adult units (Cryo 5 units = Fibtem A5 increase of approx 2mm)

FIBRINOLYSIS

FIBRINOGEN

PLATELETS

CTORS



Prothrombinex

- Warfarin Reversal: Indicated for urgent reversal of warfarin in critical bleeding, usual dose 25-50U/kg (+/-FFP) discuss with haematologist.
- Consider as an alternative to FFP for patients with coagulation factor deficiency (e.g. prolonged EXTEM CT see above) in the following circumstances:
- Circulatory overload
- Rapid correction in extreme coagulopathy
- Consider lower dose 10U/kg (round to nearest 500U).

FSH ROTEM Algorithm for Critical Bleeding


This algorithm should be used in conjunction with the FSH Major Haemorrhage Protocol Treat abnormal values only if there is active bleeding or the patients is at high risk of bleeding. Repeat ROTEM analysis 10 mins after any intervention to assess response.

	ABNORMAL ROTEM	CRITERIA	DIAGNOSIS	INTERVENTION	CORRECTED ROTEM	
RINOLYSIS	17 15 15 17 17 17 17 17 17 17 17 17 17 17 17 17	Trauma (within 3hrs) OR Post partum haemorrhage		Tranexamic acid 1g	Priority of the state of the st	
FIBRIN		Flat trace OR Maximal lysis >5%	Hyperfibrinolysis		9472 67 mm 942 8 9 72 *	
FIBRINOGEN	10 (1994) 10 (1994) 10 (1994) 10 (1994) 10 (1994) 10 (1994) 11 (1994) 12 (1994) 13 (1994) 14 (1994) 15 (1994) 16 (1994) 17 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (1994) 18 (19	FIBTEM A5 ≤10mm	Hypofibrinogenaemia	Cryoprecipitate	The control The control	
PLATELETS	57 244 (K) 57 244 (K) 57 354 (K) 57 354 (K) 57 35 (K) 68 48 (K) 68 48 (K) 68 25 (M)	EXTEM A5 ≤35mm with normal fibrinogen*	Thrombocytopaenia	Platelets	7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
FACTORS	15 (1705) 15 (1705)	EXTEM CT 90-140sec with normal fibrinogen** OR EXTEM CT >140sec	Low coagulation factors	Fresh Frozen Plasma 2-4u OR Prothrombinex 25IU/kg	C 2010 C 2010 C 2010 C 3 500 C 3 50	
	Cryonrecipitate Dosing Guide					


Cryoprecipitate Dosing Guide					
FIBTEM A5	Non-obstetric	Obstetric			
7-10	1 dose	2 doses			
<6	2 doses	3 doses			
One dose = five apheresis units = Fibtem A5 increase of approximately 4mm					

^{*}If EXTEM <25 and FIBTEM A5 <10 consider replacing both factors

[&]quot;*Fibrinogen replacement in the context of hypofibrinogenaemia may overcome a minor prolongation of clotting time



Key components					
Thrombin generation					
Fibrinogen and platelet concentration and function					
concentration and function					
Fibrinogen concentration and function					
Degree of fibrinolysis over temogram					



Please stick this label in the patients progress notes

ROTEM ANALYSIS AND TREATMENT PLAN

Nurse or JMO to circle algorithm used then insert results from ROTEM Next circle range (action red range) and use algorithm to create a plan.

Date: / / Time:

ALGORITHM USED (circle one):

CARDIAC/VASCULAR or GENERAL/OBSTETRIC

• For CARDIAC/VASCULAR start here and do all:

INTEM CT = Below 205 / 205 & Above HEPTEM CT = Below 205 / 205 & Above

For GENERAL/OBSTETRIC start here(this section only):

EXTEM A5 = Below 35 / 35-40 / Above 40

FIBTEM A5 = Below 10 / 10-15 / Above 15

EXTEM CT =..... Below 80 / 80-90 / Above 90

EXTEM ML =.....Below 5 / 5 & Above

Management Plan:

Please stick this label in the patients progress notes